CNS Pharmaceuticals Files Current Report
Ticker: CNSP · Form: 8-K · Filed: 2024-12-11T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Update
TL;DR
CNS Pharmaceuticals filed an 8-K, likely containing updates. Check for details.
AI Summary
On December 11, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's current report status and financial statements and exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates CNS Pharmaceuticals, Inc. is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific material events or financial data that would indicate a high risk.
Key Players & Entities
- CNS Pharmaceuticals, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Houston, Texas (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for CNS Pharmaceuticals, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating it reports on significant events or information.
When was the earliest event reported in this filing?
The earliest event reported is dated December 11, 2024.
In which state is CNS Pharmaceuticals, Inc. incorporated?
CNS Pharmaceuticals, Inc. is incorporated in Nevada.
What is the principal executive office address for CNS Pharmaceuticals, Inc.?
The principal executive offices are located at 2100 West Loop South, Suite 900, Houston, Texas 77027.
What is the company's telephone number as listed in the filing?
The company's telephone number is (800) 946-9185.
Filing Stats: 497 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-11 12:24:58
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
Filing Documents
- cns_8k.htm (8-K) — 27KB
- cns_ex9901.htm (EX-99.1) — 44KB
- image_001.jpg (GRAPHIC) — 61KB
- image_002.jpg (GRAPHIC) — 154KB
- image_003.jpg (GRAPHIC) — 60KB
- image_004.jpg (GRAPHIC) — 115KB
- image_005.jpg (GRAPHIC) — 134KB
- image_006.jpg (GRAPHIC) — 104KB
- image_007.jpg (GRAPHIC) — 87KB
- image_008.jpg (GRAPHIC) — 76KB
- image_009.jpg (GRAPHIC) — 96KB
- image_010.jpg (GRAPHIC) — 63KB
- image_011.jpg (GRAPHIC) — 87KB
- image_012.jpg (GRAPHIC) — 95KB
- image_013.jpg (GRAPHIC) — 97KB
- image_014.jpg (GRAPHIC) — 68KB
- image_015.jpg (GRAPHIC) — 75KB
- image_016.jpg (GRAPHIC) — 89KB
- image_017.jpg (GRAPHIC) — 118KB
- image_018.jpg (GRAPHIC) — 117KB
- image_019.jpg (GRAPHIC) — 101KB
- image_020.jpg (GRAPHIC) — 84KB
- image_021.jpg (GRAPHIC) — 80KB
- image_022.jpg (GRAPHIC) — 96KB
- image_023.jpg (GRAPHIC) — 132KB
- image_024.jpg (GRAPHIC) — 94KB
- image_025.jpg (GRAPHIC) — 84KB
- image_026.jpg (GRAPHIC) — 73KB
- image_027.jpg (GRAPHIC) — 91KB
- image_028.jpg (GRAPHIC) — 83KB
- image_029.jpg (GRAPHIC) — 97KB
- image_030.jpg (GRAPHIC) — 60KB
- image_031.jpg (GRAPHIC) — 93KB
- image_032.jpg (GRAPHIC) — 87KB
- image_033.jpg (GRAPHIC) — 87KB
- image_034.jpg (GRAPHIC) — 124KB
- image_035.jpg (GRAPHIC) — 65KB
- image_036.jpg (GRAPHIC) — 108KB
- image_037.jpg (GRAPHIC) — 79KB
- image_038.jpg (GRAPHIC) — 96KB
- image_039.jpg (GRAPHIC) — 101KB
- image_040.jpg (GRAPHIC) — 84KB
- image_041.jpg (GRAPHIC) — 86KB
- image_042.jpg (GRAPHIC) — 50KB
- image_043.jpg (GRAPHIC) — 68KB
- image_044.jpg (GRAPHIC) — 56KB
- 0001683168-24-008640.txt ( ) — 5705KB
- cnsp-20241211.xsd (EX-101.SCH) — 3KB
- cnsp-20241211_lab.xml (EX-101.LAB) — 33KB
- cnsp-20241211_pre.xml (EX-101.PRE) — 24KB
- cns_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On December 11, 2024, CNS Pharmaceuticals, Inc. (the "Company"), will hold a virtual analyst and investor day meeting at which the presentation set forth in Exhibit 99.1 will be reviewed. The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit Description 99.1 P resentation dated December 11, 2024 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: December 11, 2024 3